| Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 08/23 09:00 | globenewswire.com |
| Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript | 08/13 12:39 | seekingalpha.com |
| Nuwellis, Inc. Announces Second Quarter 2024 Financial Results | 08/13 08:00 | globenewswire.com |
| Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's | 07/26 09:00 | globenewswire.com |
| Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules | 07/24 08:02 | globenewswire.com |
| Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 | 07/23 16:10 | globenewswire.com |
| Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's | 07/17 09:00 | globenewswire.com |
| Nuwellis Announces Reverse Stock Split | 06/26 08:45 | globenewswire.com |
| Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™ | 06/25 09:00 | globenewswire.com |
| DaVita, Nuwellis Extend Pilot Collaboration for Aquadex | 06/11 12:46 | benzinga.com |